Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications - investor.lilly.com

Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications investor.lilly.com Lilly shares safety, tolerability data on its next-gen obesity drug statnews.com Eli Lilly says next-gen obesity drug curbs sleep apnea, among other benefits Reuters A new wave of weight-loss therapies aims to be better than today’s GLP-1s MarketWatch ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes Fierce Biotech